Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 7 studies | 23% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 2147.93 | 242 / 245 | 99% | 46.76 | 498 / 502 |
uterus | 100% | 1146.71 | 170 / 170 | 97% | 74.19 | 444 / 459 |
breast | 100% | 1661.44 | 459 / 459 | 96% | 61.79 | 1076 / 1118 |
stomach | 100% | 1247.25 | 359 / 359 | 96% | 38.63 | 274 / 286 |
esophagus | 98% | 1298.62 | 1423 / 1445 | 97% | 49.09 | 178 / 183 |
intestine | 99% | 1548.24 | 954 / 966 | 97% | 38.21 | 510 / 527 |
thymus | 100% | 2533.24 | 653 / 653 | 95% | 30.99 | 577 / 605 |
ovary | 99% | 1026.18 | 178 / 180 | 96% | 63.06 | 411 / 430 |
lung | 100% | 2713.10 | 577 / 578 | 94% | 51.26 | 1086 / 1155 |
liver | 100% | 3415.00 | 226 / 226 | 93% | 40.27 | 377 / 406 |
skin | 90% | 1144.51 | 1628 / 1809 | 94% | 50.47 | 446 / 472 |
kidney | 100% | 2371.47 | 89 / 89 | 83% | 26.71 | 744 / 901 |
bladder | 86% | 925.76 | 18 / 21 | 91% | 47.72 | 457 / 504 |
pancreas | 74% | 582.01 | 243 / 328 | 94% | 52.23 | 167 / 178 |
brain | 76% | 592.24 | 1998 / 2642 | 73% | 20.52 | 517 / 705 |
adrenal gland | 71% | 486.24 | 183 / 258 | 44% | 9.87 | 101 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 121.60 | 29 / 29 |
spleen | 100% | 5385.21 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 78.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.12 | 1 / 1 |
peripheral blood | 100% | 7773.43 | 928 / 929 | 0% | 0 | 0 / 0 |
adipose | 100% | 1635.13 | 1200 / 1204 | 0% | 0 | 0 / 0 |
heart | 95% | 903.84 | 815 / 861 | 0% | 0 | 0 / 0 |
muscle | 91% | 908.18 | 730 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 90% | 859.62 | 1208 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 63% | 18.88 | 50 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002376 | Biological process | immune system process |
GO_0019043 | Biological process | establishment of viral latency |
GO_0032728 | Biological process | positive regulation of interferon-beta production |
GO_2000110 | Biological process | negative regulation of macrophage apoptotic process |
GO_0060340 | Biological process | positive regulation of type I interferon-mediated signaling pathway |
GO_0034127 | Biological process | regulation of MyD88-independent toll-like receptor signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0009615 | Biological process | response to virus |
GO_0051607 | Biological process | defense response to virus |
GO_0006974 | Biological process | DNA damage response |
GO_0034124 | Biological process | regulation of MyD88-dependent toll-like receptor signaling pathway |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0032727 | Biological process | positive regulation of interferon-alpha production |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0032479 | Biological process | regulation of type I interferon production |
GO_0050776 | Biological process | regulation of immune response |
GO_0002819 | Biological process | regulation of adaptive immune response |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0045655 | Biological process | regulation of monocyte differentiation |
GO_0002753 | Biological process | cytoplasmic pattern recognition receptor signaling pathway |
GO_0039530 | Biological process | MDA-5 signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010008 | Cellular component | endosome membrane |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IRF7 |
Protein name | Interferon regulatory factor 7, isoform CRA_c (cDNA FLJ61529, highly similar to Interferon regulatory factor 7) Interferon regulatory factor 7 (IRF-7) Interferon regulatory factor 7 |
Synonyms | hCG_18132 |
Description | FUNCTION: Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses . Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters . Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction via both the virus-activated, MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway. Induces transcription of ubiquitin hydrolase USP25 mRNA in response to lipopolysaccharide (LPS) or viral infection in a type I IFN-dependent manner (By similarity). Required during both the early and late phases of the IFN gene induction but is more critical for the late than for the early phase. Exists in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, becomes phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization where along with other coactivators it can activate transcription of the type I IFN and ISG genes. Can also play a role in regulating adaptive immune responses by inducing PSMB9/LMP2 expression, either directly or through induction of IRF1. Binds to the Q promoter (Qp) of EBV nuclear antigen 1 a (EBNA1) and may play a role in the regulation of EBV latency. Can activate distinct gene expression programs in macrophages and regulate the anti-tumor properties of primary macrophages (By similarity) . . |
Accessions | ENST00000330243.9 [Q92985-4] A0A3B3ISC0 ENST00000612534.4 [Q92985-4] ENST00000647801.1 ENST00000621391.4 [Q92985-1] A0A3B3ISS4 ENST00000617397.1 A0A3B3ITQ5 ENST00000469048.6 [Q92985-3] E9PSE3 ENST00000633274.1 [Q92985-3] ENST00000532326.5 ENST00000533182.5 [Q92985-3] ENST00000634105.1 [Q92985-3] ENST00000649187.1 ENST00000632194.1 ENST00000348655.11 [Q92985-2] M9RSF4 ENST00000631879.1 ENST00000633943.1 [Q92985-2] B4E1B1 ENST00000397570.5 E9PIA7 ENST00000528413.6 ENST00000397566.5 [Q92985-4] ENST00000632827.1 [Q92985-4] ENST00000525445.6 [Q92985-1] Q92985 |